Acute cardiac care & resuscitationCohort study
Midterm Outcomes of Patients with Native Heart Recovery After Impella 5+ for Cardiogenic Shock
- Retrospective cohort study
- single-centre
- Mean Impella support duration 10.5 ± 8 days
Authors' conclusion
Impella 5+ represents a promising treatment strategy for CS, providing high rates of sustained native heart recovery.
Study context
- Population
- Patients with cardiogenic shock supported by Impella 5+ and discharged with heart recovery, June 2022–April 2024
- Participants
- 20 patients
- Outcome
- Survival and freedom from ICD, heart transplant/LVAD or readmission for HF
- Follow-up
- 180 days
Main finding
As reported in the abstract
180-day survival and freedom from ICD, heart transplant/LVAD or HF readmission
Alive
19 (95%)
Heart transplant/LVAD
0
Implantable cardioverter-defibrillator (ICD) implanted
40%
HF admissions
2
Observational data: associations, not effects.
Further findings
Left ventricular ejection fraction (LVEF) · 180 days
- Mean LVEF at 180 days
- 33.5 ± 10.7%
- Mean LVEF before Impella
- 19.2 ± 5.2%
New York Heart Association (NYHA) class · 180 days
- NYHA class I
- 5 (26.3%)
- NYHA class II
- 9 (47.4%)
- NYHA class III
- 5 (26.3%)
Original publication
Midterm Outcomes of Patients with Native Heart Recovery After Impella 5+ for Cardiogenic Shock. Eur J Heart Fail. Published 1 December 2024. doi:10.1002/ejhf.3544
Summarised from the published abstract; every number is checked against it